SK bioscience Co.,Ltd. (KRX:302440)
South Korea
· Delayed Price · Currency is KRW 42,850
-150 (-0.35%)
At close: May 28, 2025, 3:30 PM KST
SK bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 399,832 | 267,545 | 369,506 | 456,726 | 929,001 |
| Other Revenue | 0 | - | - | -0 | - |
| Revenue | 399,832 | 267,545 | 369,506 | 456,726 | 929,001 |
| Revenue Growth (YoY) | 7.72% | -27.59% | -19.10% | -50.84% | - |
| Cost of Revenue | 349,083 | 237,466 | 227,681 | 217,443 | 358,968 |
| Gross Profit | 50,749 | 30,079 | 141,824 | 239,283 | 570,033 |
| Selling, General & Admin | 98,001 | 87,056 | 60,841 | 61,801 | 46,027 |
| Research & Development | 66,076 | 71,353 | 85,743 | 57,960 | 47,250 |
| Other Operating Expenses | 1,232 | 1,274 | 1,417 | 664.99 | 388.56 |
| Operating Expenses | 176,204 | 168,511 | 153,812 | 124,269 | 95,813 |
| Operating Income | -125,455 | -138,431 | -11,988 | 115,014 | 474,220 |
| Interest Expense | -5,841 | -3,685 | -1,398 | -2,461 | -3,427 |
| Interest & Investment Income | 8,471 | 6,978 | 13,555 | 4,854 | 1,517 |
| Currency Exchange Gain (Loss) | -4,147 | 3,137 | 13,325 | 16,506 | -1,662 |
| Other Non Operating Income (Expenses) | 7,617 | 4,474 | -18,722 | -28,620 | -434.77 |
| EBT Excluding Unusual Items | -119,357 | -127,527 | -5,228 | 105,293 | 470,212 |
| Gain (Loss) on Sale of Investments | 22,103 | 24,162 | 13,777 | 36,875 | 892.14 |
| Gain (Loss) on Sale of Assets | 14,152 | 14,259 | -68.06 | -434.6 | 23.62 |
| Asset Writedown | -1.41 | -1.41 | -1,154 | - | - |
| Pretax Income | -83,104 | -89,107 | 7,327 | 141,733 | 471,128 |
| Income Tax Expense | -42,633 | -38,990 | -14,990 | 19,281 | 115,989 |
| Earnings From Continuing Operations | -40,470 | -50,117 | 22,318 | 122,452 | 355,139 |
| Minority Interest in Earnings | -7,158 | -3,764 | - | - | - |
| Net Income | -47,629 | -53,881 | 22,318 | 122,452 | 355,139 |
| Net Income to Common | -47,629 | -53,881 | 22,318 | 122,452 | 355,139 |
| Net Income Growth | - | - | -81.77% | -65.52% | - |
| Shares Outstanding (Basic) | 78 | 77 | 77 | 77 | 73 |
| Shares Outstanding (Diluted) | 78 | 77 | 77 | 77 | 74 |
| Shares Change (YoY) | 0.92% | 0.24% | -0.01% | 4.32% | - |
| EPS (Basic) | -613.07 | -697.93 | 290.65 | 1596.18 | 4844.07 |
| EPS (Diluted) | -613.14 | -698.00 | 290.00 | 1590.00 | 4810.00 |
| EPS Growth | - | - | -81.76% | -66.94% | - |
| Free Cash Flow | -165,547 | -292,433 | -14,114 | -197,951 | 493,686 |
| Free Cash Flow Per Share | -2130.90 | -3787.93 | -183.27 | -2570.08 | 6686.61 |
| Gross Margin | 12.69% | 11.24% | 38.38% | 52.39% | 61.36% |
| Operating Margin | -31.38% | -51.74% | -3.24% | 25.18% | 51.05% |
| Profit Margin | -11.91% | -20.14% | 6.04% | 26.81% | 38.23% |
| Free Cash Flow Margin | -41.40% | -109.30% | -3.82% | -43.34% | 53.14% |
| EBITDA | -64,189 | -89,206 | 22,777 | 142,250 | 492,995 |
| EBITDA Margin | -16.05% | -33.34% | 6.16% | 31.15% | 53.07% |
| D&A For EBITDA | 61,267 | 49,225 | 34,765 | 27,236 | 18,775 |
| EBIT | -125,455 | -138,431 | -11,988 | 115,014 | 474,220 |
| EBIT Margin | -31.38% | -51.74% | -3.24% | 25.18% | 51.05% |
| Effective Tax Rate | - | - | - | 13.60% | 24.62% |
| Advertising Expenses | - | 2,296 | 1,849 | 1,190 | 1,909 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.